PURPOSE: To investigate whether cerebral blood volume (CBV), peak height (PH), and percentage of signal intensity recovery (PSR) measurements derived from the results of T2-weighted dynamic susceptibility-weighted contrast material-enhanced (DSC) magnetic resonance (MR) imaging performed after external beam radiation therapy (EBRT) can be used to distinguish recurrent glioblastoma multiforme (GBM) from radiation necrosis. MATERIALS AND METHODS: Fifty-seven patients were enrolled in this HIPAA-compliant institutional review board-approved retrospective study after they received a diagnosis of GBM, underwent EBRT, and were examined with DSC MR imaging, which revealed progressive contrast enhancement within the radiation field. A definitive diagnosis was established at subsequent surgical resection or clinicoradiologic follow-up. Regions of interest were retrospectively drawn around the entire contrast-enhanced region. This created T2-weighted signal intensity-time curves that produced three cerebral hemodynamic MR imaging measurements: CBV, PH, and PSR. Welch t tests were used to compare measurements between groups. RESULTS: Mean, maximum, and minimum relative PH and relative CBV were significantly higher (P < .01) in patients with recurrent GBM than in patients with radiation necrosis. Mean, maximum, and minimum relative PSR values were significantly lower (P < .05) in patients with recurrent GBM than in patients with radiation necrosis. CONCLUSION: These findings suggest that DSC perfusion MR imaging may be used to differentiate recurrent GBM from EBRT-induced radiation necrosis. (c) RSNA, 2009.
PURPOSE: To investigate whether cerebral blood volume (CBV), peak height (PH), and percentage of signal intensity recovery (PSR) measurements derived from the results of T2-weighted dynamic susceptibility-weighted contrast material-enhanced (DSC) magnetic resonance (MR) imaging performed after external beam radiation therapy (EBRT) can be used to distinguish recurrent glioblastoma multiforme (GBM) from radiation necrosis. MATERIALS AND METHODS: Fifty-seven patients were enrolled in this HIPAA-compliant institutional review board-approved retrospective study after they received a diagnosis of GBM, underwent EBRT, and were examined with DSC MR imaging, which revealed progressive contrast enhancement within the radiation field. A definitive diagnosis was established at subsequent surgical resection or clinicoradiologic follow-up. Regions of interest were retrospectively drawn around the entire contrast-enhanced region. This created T2-weighted signal intensity-time curves that produced three cerebral hemodynamic MR imaging measurements: CBV, PH, and PSR. Welch t tests were used to compare measurements between groups. RESULTS: Mean, maximum, and minimum relative PH and relative CBV were significantly higher (P < .01) in patients with recurrent GBM than in patients with radiation necrosis. Mean, maximum, and minimum relative PSR values were significantly lower (P < .05) in patients with recurrent GBM than in patients with radiation necrosis. CONCLUSION: These findings suggest that DSC perfusion MR imaging may be used to differentiate recurrent GBM from EBRT-induced radiation necrosis. (c) RSNA, 2009.
Authors: J S Taylor; P S Tofts; R Port; J L Evelhoch; M Knopp; W E Reddick; V M Runge; N Mayr Journal: J Magn Reson Imaging Date: 1999-12 Impact factor: 4.813
Authors: C Dowling; A W Bollen; S M Noworolski; M W McDermott; N M Barbaro; M R Day; R G Henry; S M Chang; W P Dillon; S J Nelson; D B Vigneron Journal: AJNR Am J Neuroradiol Date: 2001-04 Impact factor: 3.825
Authors: Jack P Rock; David Hearshen; Lisa Scarpace; David Croteau; Jorge Gutierrez; James L Fisher; Mark L Rosenblum; Tom Mikkelsen Journal: Neurosurgery Date: 2002-10 Impact factor: 4.654
Authors: N Sadeghi; N D'Haene; C Decaestecker; M Levivier; T Metens; C Maris; D Wikler; D Baleriaux; I Salmon; S Goldman Journal: AJNR Am J Neuroradiol Date: 2007-12-13 Impact factor: 3.825
Authors: T Sugahara; Y Korogi; S Tomiguchi; Y Shigematsu; I Ikushima; T Kira; L Liang; Y Ushio; M Takahashi Journal: AJNR Am J Neuroradiol Date: 2000-05 Impact factor: 4.966
Authors: R F Barajas; D Schwartz; H L McConnell; C N Kersch; X Li; B E Hamilton; J Starkey; D R Pettersson; J P Nickerson; J M Pollock; R F Fu; A Horvath; L Szidonya; C G Varallyay; J J Jaboin; A M Raslan; A Dogan; J S Cetas; J Ciporen; S J Han; P Ambady; L L Muldoon; R Woltjer; W D Rooney; E A Neuwelt Journal: AJNR Am J Neuroradiol Date: 2020-06-11 Impact factor: 3.825
Authors: Asim K Bag; Phillip C Cezayirli; Jake J Davenport; Santhosh Gaddikeri; Hassan M Fathallah-Shaykh; Alan Cantor; Xiaosi S Han; Louis B Nabors Journal: J Neurooncol Date: 2014-08-07 Impact factor: 4.130
Authors: Joshua T McKenzie; Jess N Guarnaschelli; Achala S Vagal; Ronald E Warnick; John C Breneman Journal: J Neurooncol Date: 2013-04-16 Impact factor: 4.130
Authors: Melissa A Prah; Mona M Al-Gizawiy; Wade M Mueller; Elizabeth J Cochran; Raymond G Hoffmann; Jennifer M Connelly; Kathleen M Schmainda Journal: J Neurooncol Date: 2017-09-12 Impact factor: 4.130